1. Market Research
  2. > Pharmaceutical Market Trends
The Chinese Market for Cancer Intervention

The Chinese Market for Cancer Intervention

  • June 2017
  • 130 pages
  • ID: 4977682
  • Format: PDF
  • BCC Research

Summary

Table of Contents

• The Chinese cancer intervention market reached nearly $41.1 billion in 2016. This market should reach $46.7 billion in 2017 and $89.3 billion by 2022, at a compound annual growth rate (CAGR) of 13.8% through 2022.
• Cancer treatment services as a segment should reach nearly $43.9 billion in 2017 and $83.6 billion by 2022, at a CAGR of 13.8% through 2022.
• Diagnosis and detection services as a segment should reach nearly $2.9 billion in 2017 and $5.8 billion by 2022, at a CAGR of 15.0% through 2022.

Chapter 1: Introduction


Study Goals and Objectives
The Chinese cancer intervention market is big, fast-growing, and dominated by drug and equipment suppliers from outside China. This market is very important for pharmaceutical companies in North America, Europe and other developed regions and which are looking for strong growth and high profits in the following decade. The goal of this study is to help readers achieve a comprehensive understanding of the recent advances and trends in the cancer intervention industry and market in China. Toward this end, this report will cover the market for products for different types of cancer to 2022. The report provides a comprehensive discussion of cancer intervention applications, industry structure, marketing and distribution, partnerships, and companies. The report is designed to aid companies in their strategic planning efforts for accessing cancer intervention industry opportunities in the Chinese market.


Reasons for Doing This Study
This study will help pharmaceutical companies, medical equipment suppliers, medical institutions, and drug wholesalers and distributors gain an in-depth understanding on the Chinese cancer intervention market.


Scope of Report
The scope of the report includes cancer intervention applications, industries, markets, and companies in China. The markets for cancer intervention are given for the years 2016, 2017 and 2022. The Chinese cancer intervention market includes two major segments: cancer treatment and cancer diagnosis and detection. Each major segment will be further divided and discussed by technology, drug type, end user, etc. In this report, China is referred to as Mainland China. It does not include Hong Kong, Macao and Taiwan. Mainland China has a total of 31 province-level regions, including 22 provinces, four province-level municipalities (cities), and five province-level autonomous regions. Important geographic markets will be discussed, including Beijing, Shanghai and others.


Information Sources
Information sources for this report include experts, executives, professors, and officials in the Chinese cancer intervention industry. They are from pharmaceutical companies, associations and governmental departments. Information sources for the study also include online research, patent literature, technical journals, trade magazines, governmental data, public speeches, and conference papers.


Methodology
Both primary and secondary research methodologies were used in preparing this study. Estimates of current market demand are made for 2016 and are projected for the next five years from 2017 through 2022. Projections are made in terms of constant U.S. dollars (2016), unadjusted for inflation. Growth is presented in terms of a compound average annual growth rate (CAGR). Sales values are measured at end consumer level; reasons are discussed in the report.


Geographic Breakdown
In this report, the geographic regions considered for market analysis include, and only include:
North China
• Beijing
• Hebei
• Shanxi
• Tianjin
• Inner Mongolia
East China
• Shanghai
• Shandong
• Zhejiang
• Jiangsu
• Fujian
• Anhui
South China
• Guangdong
• Guangxi
• Hainan
Middle China
• Hubei
• Henan
• Hunan
• Jiangxi
Northwest China
• Shaanxi
• Xinjiang
• Gansu
• Qinghai
• Ningxia

Southwest China
• Sichuan
• Chongqing
• Yunnan
• Guizhou
• Tibet
Northeast China
• Liaoning
• Heilongjiang
• Jilin

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Catenin Beta 1 - Pipeline Review, H2 2020

  • $ 3500
  • November 2020
  • 69 pages

Catenin Beta 1 - Pipeline Review, H2 2020 Summary Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by ...

  • World
  • Cancer
  • Pharmaceutical
  • Industry analysis
  • Biologics Production
  • Manufacturing Output

ref:plp2017

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on